Clinical trials: Differentiated Thyroid Cancer
Thyroid Cancer
Study of Apatinib in Patients With Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
- Trial name
- NCT02731352
- Testing
- Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Cancer
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
The purpose of this study is to determine the effectiveness of two anticancer drugs, everolimus and pasireotide, in patients with thyroid cancer when the cancer is no longer responding to treatment with radioiodine or where it is…
- Trial name
- NCT01270321
- Testing
- Everolimus, Pasireotide, Everolimus and Pasireotide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Differentiated Thyroid Cancer
A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
This trial is a prospective, non-interventional, monocentric study aiming to collect standard of care imaging of patients treated with Iodine-131 for the determination of dosimetric studies.
- Trial name
- MEDIRAD (NCT03986437)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud
Thyroid Cancer
Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers
This is a multicenter randomized controlled trial including patients with small (<2 cm) suspected or confirmed thyroid cancers. Patients are included after informed consent and randomized to one of two treatments.
- Trial name
- NCT06796348
- Testing
- Radiofrequency ablation alone, Surgery
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- University of Aarhus
Low Risk Differentiated Thyroid Cancer
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Open-label randomized phase III trial, using a non-inferiority comparison design. After randomization,patients will receive either post-operative radioiodine ablation with an activity of 1.1 GBq (30 mCi) after stimulation by…
- Trial name
- ESTIMABL2 (NCT01837745)
- Testing
- rhTSH stimulation, I131, Follow up
- Where
- France
- Volunteers
- 776 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
DTC - Differentiated Thyroid Cancer
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.
- Trial name
- NCT05007093
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Yansong Lin
Thyroid Cancer, Thyroid Cancer, Follicular
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
- Conditions
- Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer
- Trial name
- NCT04544111
- Testing
- Trametinib, Dabrafenib, PDR001
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Cancer of the Thyroid
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
- Trial name
- NCT07092514
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Thyroid Cancer
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty…
- Trial name
- NCT05275946
- Testing
- Targeted alpha therapy
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Osaka University
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Differentiated Thyroid Gland Carcinoma
COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer
Most thyroid cancers can be cured with surgery, sometimes with radioactive iodine therapy. However, some patients have cancer that has spread, and some have cancer that comes back after treatment.
- Trial name
- NCT06790589
- Testing
- Levothyroxine Oral Tablet [Synthroid]
- Volunteers
- 70 people
- Sponsor
- AHS Cancer Control Alberta
Thyroid Neoplasms
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).
- Trial name
- NCT03573960
- Testing
- Lenvatinib
- Where
- 11 sites in India
- Volunteers
- 50 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Well Differentiated Thyroid Carcinoma, Papillary Thyroid Cancer
The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience
Background After diagnosing well-differentiated thyroid cancer (WDTC), careful assessment of the risk for disease-specific recurrence is essential for deciding between partial (low risk) and completion (high risk)…
- Trial name
- NCT04500925
- Testing
- UNILATERAL THYROIDECTOMY
- Volunteers
- 301 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Thyroid Gland Carcinoma
Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
This study is being done to identify and differentiate thyroid nodules by acoustic imaging and viscoelastic parameters.
- Trial name
- NCT06207188
- Testing
- Non-Interventional Study
- Where
- 3 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Thyroid Neoplasms
Study of Clinical Outcomes of Thyroid Cancer
The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on thyroid cancer management in a prospective and consecutive series of newly-diagnosed patients, enrolled in centers uniformly distributed…
- Trial name
- ITCO (NCT04031339)
- Testing
- Standard treatment
- Where
- 35 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Roma La Sapienza
Differentiated Thyroid Cancer, Pediatric Cancer
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- RAISE (NCT06458036)
- Testing
- Selpercatinib Monotherapy, 131I Therapy
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Differentiated Thyroid Cancer
Iodine Uptake After a Low Iodine Diet
The goal of this clinical trial is to compare the difference in thyroid uptake of a low dose radioactive iodine (10 MBq 123-I or 37 MBq 123-I) in athyreotic patients with differentiated thyroid carcinoma before and after a low…
- Trial name
- IULID (NCT05599139)
- Testing
- Low iodine diet
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- University Medical Center Groningen
Thyroid Neoplasm Follicular, Bone Metastases
Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases
Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone…
- Trial name
- NCT05466812
- Testing
- Sr-89
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)